Literature DB >> 12234607

The activity profile of the hexacyclic camptothecin derivative DX-8951f in experimental human colon cancer and ovarian cancer.

Annemarie H van Hattum1, Herbert M Pinedo, Hennie M M Schlüper, Caroline A M Erkelens, Akiko Tohgo, Epie Boven.   

Abstract

DX-8951f or exatecan mesylate ((1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy-4-methyl-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinoline-10-13(9H,15H)-dione methanesulfonate dihydrate), is a new water-soluble derivative of camptothecin. We determined the activity of DX-8951f in experimental human colon cancer and ovarian cancer, being tumor types sensitive to camptothecins. With the use of the MTT assay, DX-8951f was more potent than SN-38 in four out of five human colon cancer cell lines and three out of four human ovarian cancer cell lines (P<0.05). DX-8951f was considerably more potent than topotecan in all cell lines tested (P<0.05). Prolonged exposure to DX-8951f resulted in a greater increase in inhibition of cell proliferation as compared to that obtained with SN-38 or topotecan (P<0.05). Overexpression of Pgp, MRP1, and LRP did not affect the in vitro activity of DX-8951f. DX-8951f administered daily x 5 or weekly x 2 resulted in growth inhibition <50% in two human colon cancer xenografts grown s.c. in nude mice. In three human ovarian cancer xenografts, however, >50% growth inhibition was observed at both schedules. In the OVCAR-3 human ovarian cancer model, DX-8951f showed considerably greater activity than topotecan (P<0.01). DX-8951f combined with cisplatin or paclitaxel did not indicate the presence of a pharmacological interaction. In OVCAR-3 xenografts the combination was clearly more effective than DX-8951f alone, as the number of complete remissions increased substantially. In conclusion, this study shows that DX-8951f is highly potent in vitro and highly effective in experimental human ovarian cancer in vivo. Prolonged exposure to DX-8951f in vitro greatly increased the antiproliferative effects, which may be a rationale for testing a continuous infusion schedule in the clinic. Addition of cisplatin or paclitaxel improved the in vivo antitumor effects of DX-8951f.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12234607     DOI: 10.1016/s0006-2952(02)01297-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  4 in total

Review 1.  Perspectives on biologically active camptothecin derivatives.

Authors:  Ying-Qian Liu; Wen-Qun Li; Susan L Morris-Natschke; Keduo Qian; Liu Yang; Gao-Xiang Zhu; Xiao-Bing Wu; An-Liang Chen; Shao-Yong Zhang; Xiang Nan; Kuo-Hsiung Lee
Journal:  Med Res Rev       Date:  2015-03-21       Impact factor: 12.944

2.  Anti-tumor activity of N-trimethyl chitosan-encapsulated camptothecin in a mouse melanoma model.

Authors:  Xian-Ping Liu; Sheng-Tao Zhou; Xing-Yi Li; Xian-Cheng Chen; Xia Zhao; Zhi-Yong Qian; Li-Na Zhou; Zhi-Yong Li; Yu-Mei Wang; Qian Zhong; Tao Yi; Zheng-Yu Li; Xiang He; Yu-Quan Wei
Journal:  J Exp Clin Cancer Res       Date:  2010-06-17

3.  Camptothecin nanocolloids based on N,N,N-trimethyl chitosan: efficient suppression of growth of multiple myeloma in a murine model.

Authors:  Zhengguang Li; Xingyi Li; Zhixing Cao; Youzhi Xu; Hongjun Lin; Yinglan Zhao; Yuquan Wei; Zhiyong Qian
Journal:  Oncol Rep       Date:  2012-01-12       Impact factor: 3.906

Review 4.  Alkaloids and Colon Cancer: Molecular Mechanisms and Therapeutic Implications for Cell Cycle Arrest.

Authors:  Haroon Khan; Waqas Alam; Khalaf F Alsharif; Michael Aschner; Samreen Pervez; Luciano Saso
Journal:  Molecules       Date:  2022-01-28       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.